A Randomized-Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft LesionsThe SOS (Stenting Of Saphenous Vein Grafts) Trial
Emmanouil S. Brilakis, MD, PhD, FACC*, ,*,
Christopher Lichtenwalter, MD*,,
James A. de Lemos, MD, FACC*,,
Michele Roesle, RN*,
Owen Obel, MD*,,
Donald Haagen, RCIS*,
Bilal Saeed, MD ,
Chiranjeevi Gadiparthi, MD*,,
Joseph K. Bissett, MD, FACC ,
Rajesh Sachdeva, MD, FACC,
Vassilios V. Voudris, MD, PhD, FACC||,
Panagiotis Karyofillis, MD||,
Biswajit Kar, MD, FACC¶,
James Rossen, MD, FACC#,
Panayotis Fasseas, MD, FACC**,
Peter Berger, MD, FACC and
Subhash Banerjee, MD, FACC*,
* Veterans Affairs North Texas Healthcare System, Dallas, Texas
University of Texas Southwestern Medical Center, Dallas, Texas
Department of Internal Medicine, University of Toledo, Toledo, Ohio
Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, Arkansas
|| Onassis Cardiac Surgery Center, Athens, Greece
¶ Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
# Iowa City Veterans Affairs Medical Center, Iowa City, Iowa
** Wheaton Franciscan Medical Group, Racine, Wisconsin
Geisinger Clinic, Danville, Pennsylvania
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Flowchart of the Patients Enrolled in the SOS Trial
BMS = bare-metal stent(s); CABG = coronary artery bypass grafting; FU = follow-up; PES = paclitaxel-eluting stent(s); SOS = Stenting Of Saphenous Vein Grafts.
|
|
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 In-Stent MLD Cumulative Frequency Distributions in the 2 Study Groups
Cumulative frequency distribution curves for minimal luminal diameter (MLD) in the group that received a bare-metal stent (BMS) and in the group that received a paclitaxel-eluting stent (PES). (A) The cumulative frequency distribution curves before and immediately after the intervention. (B) The curves immediately after intervention and at 12-month follow-up angiography.
|
|
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Curves of the Study's Clinical End Points
No difference in overall mortality was found between the study groups (A). A trend for lower incidence of myocardial infarctions was seen in the paclitaxel-eluting stent (PES) group (B). The incidence of target lesion revascularization (C) and of target vessel failure (D), composite end point of cardiac death, myocardial infarction, and target vessel revascularization, was significantly lower in the PES group than the bare-metal stent (BMS) group.
|
|
|
